Company intelligence / Profile preview

Omico

Sydney, New South Wales, Australiaomico.com.au ↗

Ownership: Private
Development stage: Other

Overview

Omico has screened over 9,000 patients with advanced or rare cancers using comprehensive genomic profiling, resulting in matched treatment decisions for more than 1,000 patients. It has facilitated over fifty clinical trials—including international studies—by accelerating patient recruitment and site setup for biomarker-led precision oncology therapies. Its collaborations have enabled the development of new targeted therapies such as those addressing ALT+ cancers.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Academic Hospital/University/Research

Partnerships

Tessellate BIO (synthetic lethality/ALT+ cancer collaboration)Children’s Medical Research Institute (CMRI)Roche Australia

Beyond the preview

Go deeper on Omico.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omico.

Explore the full profile